July 31 (Bloomberg) -- Pfizer Inc.'s new chief executive officer, Jeffrey Kindler, was one of the best at charming and persuading judges and juries when he was a litigator, lawyers who worked with him say.

Teva Neuroscience announced today the launch of AZILECT® , the first, once-daily treatment for Parkinson's disease now available in pharmacies by prescription only. This is important news for the majority of respondents in a survey of those living with PD who report taking their PD medications up to five times/day.

An enzyme known to be critical for the repair of damaged cells and the maintenance of cellular energy may be a useful target for new strategies to treat Huntington's disease and other disorders characterized by low cellular energy levels. A research team from the MassGeneral Institute for Neurodegenerative Disease has discovered a novel inhibitor of Poly (ADP-ribose) polymerase (PARP1) and found

Arthritis sufferers have been warned to exercise caution with a newly-listed painkiller belonging to a family of drugs linked to increased risk of heart attacks and strokes.

Arthritis sufferers have been warned to exercise caution with a newly-listed painkiller belonging to a family of drugs linked to increased risk of heart attacks and strokes.

Arthritis sufferers are being urged to be cautious using a new painkiller belonging to a family of drugs linked to increased risk of heart attacks and strokes.

When Henry McKinnell became chief executive at Pfizer five years ago, he promised that the world's biggest drug maker would spend more on research and development than any other U.S. company.

PFIZER, the world’s biggest drugs company, has appointed Jeffrey Kindler as its next chief executive, ushering Hank McKinnnell into early retirement. Kindler, a former McDonald’s executive, was previously Pfizer’s general counsel.

Pfizer Inc. said Friday it named Vice Chairman Jeffrey B. Kindler as chief executive officer to replace Hank McKinnell, 63, who will remain chairman of the board of the world's largest drug company until his retirement in February 2007.

Jeff Kindler, vice chairman and top lawyer, is the new CEO of the world's largest drugmaker. And Hank McKinnell is out.